Updated results of the SOFT study: A randomized phase III trial of S-1/oxaliplatin (SOX) plus bevacizumab versus 5-FU/I-LV/oxaliplatin (mFOLFOX6) plus bevacizumab in patients with metastatic colorectal cancer (mCRC).

被引：1

作者：

Nakamura, Masato

Yamada, Yasuhide

Takahari, Daisuke

Matsumoto, Hiroshi

Baba, Hideo

Yoshida, Kazuhiro

Yoshida, Motoki

Iwamoto, Shigeyoshi

Shimada, Ken

Komatsu, Yoshito

Sasaki, Yasutsuna

Satoh, Taroh

Takahashi, Keiichi

Mishima, Hideyuki

Muro, Kei

Watanabe, Masahiko

Sakata, Yuh

Morita, Satoshi

Shimada, Yasuhiro

Sugihara, Kenichi

机构：

[1] Aizawa Hosp, Matsumoto, Nagano, Japan

[2] Natl Canc Ctr, Gastrointestinal Med Oncol Div, Tokyo, Japan

[3] Aichi Canc Ctr Hosp, Dept Clin Oncol, Nagoya, Aichi 464, Japan

[4] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Tokyo, Japan

[5] Kumamoto Univ, Kumamoto, Japan

[6] Gifu Univ, Sch Med, Dept Surg Oncol, Gifu 500, Japan

[7] Osaka Med Coll Hosp, Ctr Canc Chemotherapy, Osaka, Japan

[8] Kansai Med Univ, Takji Hosp, Dept Surg, Moriguchi, Osaka 570, Japan

[9] Saitama Med Univ, Hidaka, Japan

[10] Hokkaido Univ Hosp, Dept Canc Ctr, Sapporo, Hokkaido 060, Japan

[11] Showa Univ, Tokyo, Japan

[12] Osaka Univ, Osaka, Japan

[13] Komagome Hosp, Dept Surg, Tokyo Metropolitan Canc, Tokyo, Japan

[14] Komagome Hosp, Ctr Infect Dis, Tokyo, Japan

[15] Aichi Med Univ, Unit Canc Ctr, Nagakute, Aichi 48011, Japan

[16] Kitasato Univ, Sch Med, Sagamihara, Kanagawa 228, Japan

[17] Misawa City Hosp, Misawa, Japan

[18] Kyoto Univ, Grad Sch Med, Dept Biomed Stat & Bioinformat, Kyoto, Japan

[19] Tokyo Med & Dent Univ, Grad Sch, Dept Surg Oncol, Tokyo, Japan

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期

关键词：

D O I：

10.1200/jco.2014.32.15_suppl.3586

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

3586

引用

页数：1

共 50 条

[21] Phase I trial of oxaliplatin plus S-1 chemotherapy in patients with metastatic colorectal cancer
Emi, Manabu
Yamaguchi, Yoshiyuki
Hihara, Jun
Hironaka, Katsuji
Okada, Morihito
ONCOLOGY LETTERS, 2010, 1 (01) : 95 - 98
[22] A phase I trial of everolimus in combination with 5-FU/LV, mFOLFOX6 and mFOLFOX6 plus panitumumab in patients with refractory solid tumors
McRee, Autumn J.
Davies, Janine M.
Sanoff, Hanna G.
Goldberg, Richard M.
Bernard, Stephen
Dees, E. Claire
Keller, Kimberly
Ivanova, Anastasia
O'Neil, Bert H.
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 74 (01) : 117 - 123
[23] Randomized Phase II Study of S-1, Oral Leucovorin, and Oxaliplatin Combination Therapy (SOL) Versus MFOLFOX6 in Patients With Untreated Metastatic Colorectal Cancer (mCRC)
Ojima, H.
Yamazaki, K.
Kuwano, H.
Otsuji, T.
Kato, T.
Shimada, K.
Denda, T.
Esaki, T.
Hyodo, I.
Boku, N.
EUROPEAN JOURNAL OF CANCER, 2011, 47 : S427 - S428
[24] A phase I trial of everolimus in combination with 5-FU/LV, mFOLFOX6 and mFOLFOX6 plus panitumumab in patients with refractory solid tumors
Autumn J. McRee
Janine M. Davies
Hanna G. Sanoff
Richard M. Goldberg
Stephen Bernard
E. Claire Dees
Kimberly Keller
Anastasia Ivanova
Bert H. O’Neil
Cancer Chemotherapy and Pharmacology, 2014, 74 : 117 - 123
[25] BATON-CRC: A Phase II Randomized Trial Comparing Tivozanib Plus mFOLFOX6 with Bevacizumab Plus mFOLFOX6 in Stage IV Metastatic Colorectal Cancer
Benson, Al B., III
Kiss, Igor
Bridgewater, John
Eskens, Ferry A. L. M.
Sasse, Carolyn
Vossen, Sandra
Chen, Jihong
Van Sant, Chip
Ball, Howard A.
Keating, Anne
Krivoshik, Andrew
CLINICAL CANCER RESEARCH, 2016, 22 (20) : 5058 - 5067
[26] Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G)
Yamazaki, K.
Nagase, M.
Tamagawa, H.
Ueda, S.
Tamura, T.
Murata, K.
Nakajima, T. Eguchi
Baba, E.
Tsuda, M.
Moriwaki, T.
Esaki, T.
Tsuji, Y.
Muro, K.
Taira, K.
Denda, T.
Funai, S.
Shinozaki, K.
Yamashita, H.
Sugimoto, N.
Okuno, T.
Nishina, T.
Umeki, M.
Kurimoto, T.
Takayama, T.
Tsuji, A.
Yoshida, M.
Hosokawa, A.
Shibata, Y.
Suyama, K.
Okabe, M.
Suzuki, K.
Seki, N.
Kawakami, K.
Sato, M.
Fujikawa, K.
Hirashima, T.
Shimura, T.
Taku, K.
Otsuji, T.
Tamura, F.
Shinozaki, E.
Nakashima, K.
Hara, H.
Tsushima, T.
Ando, M.
Morita, S.
Boku, N.
Hyodo, I.
ANNALS OF ONCOLOGY, 2016, 27 (08) : 1539 - 1546
[27] A phase I/II, open-label, randomised study of nintedanib plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 in first-line metastatic colorectal cancer patients
Van Cutsem, E.
Prenen, H.
D'Haens, G.
Bennouna, J.
Carrato, A.
Ducreux, M.
Bouche, O.
Sobrero, A.
Latini, L.
Staines, H.
Oum'Hamed, Z.
Dressler, H.
Studeny, M.
Capdevila, J.
ANNALS OF ONCOLOGY, 2015, 26 (10) : 2085 - 2091
[28] A randomized phase II study of mFOLFOX6 plus bevacizumab versus mFOLFOX6 plus cetuximab for previously untreated, liver-limited metastatic colorectal cancer that is unsuitable for resection (ATOM trial).
Uetake, Hiroyuki
Emi, Yasunori
Yamanaka, Takeharu
Muro, Kei
Oki, Eiji
Takahashi, Takao
Nagasaka, Takeshi
Hatano, Etsuro
Ojima, Hitoshi
Manaka, Dai
Kusumoto, Tetsuya
Katayose, Yu
Fujiwara, Toshiyoshi
Yoshida, Kazuhiro
Unno, Michiaki
Hyodo, Ichinosuke
Tomita, Naohiro
Sugihara, Kenichi
Maehara, Yoshihiko
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
[29] S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: Updated results from a phase 3 trial.
Park, Young Suk
Kim, Seung
Hong, Yong Sang
Lim, Ho Yeong
Lee, Jeeyun
Kim, Tae Won
Kim, Kyu-Pyo
Kim, Sun Young
Baek, Ji Yeon
Kim, Jee Hyun
Lee, Keun-Wook
Chung, Ik-Joo
Cho, Sang-Hee
Lee, Kyung Hee
Shin, Sang Joon
Kang, Hye Jin
Shin, Dong Bok
Jo, Sook Jung
Lee, Jae Won
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[30] A Phase I/II, Open-label, Randomised Study of BIBF 1120 Plus mFOLFOX6 Compared to Bevacizumab Plus mFOLFOX6 in Patients with Metastatic Colorectal Cancer
Van Cutsem, E.
Prenen, H.
Guillen-Ponce, C.
Bennouna, J.
Di Benedetto, M.
Bouche, O.
Staines, H.
Oum'Hamed, Z.
Studeny, M.
Capdevila, J.
EUROPEAN JOURNAL OF CANCER, 2011, 47 : 8 - 9

← 1 2 3 4 5 →